Author

Jacob L. Schillo

University of Iowa

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell signaling & trafficking· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Organism:human· 1

Frequent Co-Authors

Adam J. DupuyiD· 1 shared Elizabeth C. HannaniD· 1 shared Jesse D. RiordaniD· 1 shared Keely UlmeriD· 1 shared Michael Joseph GoodheartiD· 1 shared Rebekah M. PeplinskiiD· 1 shared Silvana Pedra NobreiD· 1 shared Yasmin A. LyonsiD· 1 shared

Activity by Year

2025-2025 · peak 1/yr

Co-Author Collaboration Network

8 top collaborators · 28 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Adam J. DupuyORCID

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

Co-targeting the PI3K-Akt pathway improves response to MEK inhibition in low-grade serous ovarian cancer cell lines

Rebekah M. Peplinski, Jesse D. Riordan, Jacob L. Schillo, Elizabeth C. Hannan, Silvana Pedra Nobre, Yasmin A. Lyons, Keely Ulmer, Michael Joseph Goodheart, Adam J. Dupuy

This study shows that combining MEK and PI3K-Akt inhibition enhances anti-tumor effects in LGSOC cells and may overcome resistance to MEK inhibitors.

Gynecologic Oncology · Dec 5, 2025Peer-reviewedCancer Biology